Abstract:Rheumatoid arthritis (RA), a chronic inflammatory disease, is characterized by cartilage damage, bone tissue destruction, morphological changes in synovial fluids, and synovial joint inflammation. The inflamed synovial tissue has potential for passive and active targeting because of enhanced permeability and retention effect and the existence of RA synovial macrophages and fibroblasts that selectively express surface receptors such as folate receptor β, CD44 and integrin αVβ. Although there are numerous interventions in RA treatment, they are not safe and effective. Therefore, it is important to develop new drug or drug delivery systems that specifically targets inflamed/swollen joints but attenuates other possible damages to healthy tissues. Recently some receptors such as toll-like receptors (TLRs), the nucleotide-binding oligomerization domain-like receptors, and Fc-γ receptor have been identified in synovial tissue and immune cells that are involved in induction or suppression of arthritis. Analysis of the TLR pathway has moreover suggested new insights into the pathogenesis of RA. In the present paper, we have reviewed drug delivery strategies based on receptor targeting with novel ligand-anchored carriers exploiting CD44, folate and integrin αVβ as well as TLRs expressed on synovial monocytes and macrophages and antigen presenting cells, for possible active targeting in RA. TLRs could not only open a new horizon for developing new drugs but also their antagonists or humanized monoclonal antibodies that block TLRS specially TLR4 and TLR9 signaling could be used as targeting agents to antigen presenting cells and dendritic cells. As a conclusion, common conventional receptors and multifunctional ligands that arte involved in targeting receptors or developing nanocarriers with appropriate ligands for TLRs can provide profoundly targeting drug delivery systems for the effective treatment of RA.

Changes of transporters expression and activity in rheumatoid arthritis

Targeted Drug Delivery Strategies for the Treatment of Rheumatoid Arthritis

Progress and Research about Effects of Inflammation on Expression and Activity of Drug Transporters

Solute Carrier Transporters in Synovial Membrane and Hoffa's Pad of Patients with Rheumatoid Arthritis

[A Review on Regulation of Drug Transporters During Inflammation].

Advances of gene polymorphism affecting rheumatoid arthritis drug efficacy and adverse drug reactions

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective

The Role of Resveratrol on Rheumatoid Arthritis: from Bench to Bedside

The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritis

Advances in local drug delivery technologies for improved rheumatoid arthritis therapy

The roles of small‐molecule inflammatory mediators in rheumatoid arthritis

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

New Targets in Rheumatoid Arthritis Therapy and the Related Drugs

Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis

G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

Stimuli-responsive Drug Delivery Systems as an Emerging Platform for Treatment of Rheumatoid Arthritis.

Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment

Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies

LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation